Blocking of The Prostaglandin E2 Receptor as a Therapeutic Strategy for Treatment of Breast Cancer : Promising Findings in a Mouse Model
OBJECTIVE: The study aimed to investigate the anticancer effect of E-prostanoid receptor 1 (EP1) antagonist, SC19220, alone or in combination with the COX-2 inhibitor Celecoxob(CXB)® in mice bearing solid Ehrlich carcinoma (SEC).
METHODS: The tumors were induced in 40 female mice, which were divided randomly into four equal groups (n= 10 in each group): Tumor control, CXB, EP1 antagonist, and co-treatment. CXB (10mg/kg) and EP1 antagonist (2mg/kg) were given intraperitoneally every three days, six times in total, then tissue was extracted and prepared for histopathology and measurement of weight, PGE2, and gene expression of EP1 and β 1 integrin.
RESULTS: Both inhibitors, alone or in combination, showed a significant (p<0.001) antitumorigenic effect by decreasing, significantly (p<0.001), each of the tumor weights, tumor volumes, PGE2 levels, EP1 and β1-integrin gene expression along with increasing, significantly (p<0.001), the P53 tumor suppressor protein. The survival rate was improved from 80% in the control group to reach 100% in the treated groups. The co-treatment by CXB and EP1 antagonist showed a marked decrease in tumor weights and volumes as compared with the single treatment. In parallel, the histopathological findings showed enhanced apoptosis and diminished necrosis in the co-treated group.
CONCLUSION: EP1 antagonist proved an antitumorigenic effect alone or combined with CXB and could play a new therapeutic strategy against breast cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Asian Pacific journal of cancer prevention : APJCP - 23(2022), 11 vom: 01. Nov., Seite 3763-3770 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
El-Ashmawy, Nahla E [VerfasserIn] |
---|
Links: |
---|
Themen: |
Breast cancer |
---|
Anmerkungen: |
Date Completed 30.11.2022 Date Revised 17.02.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.31557/APJCP.2022.23.11.3763 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM34957443X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM34957443X | ||
003 | DE-627 | ||
005 | 20231226042945.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.31557/APJCP.2022.23.11.3763 |2 doi | |
028 | 5 | 2 | |a pubmed24n1165.xml |
035 | |a (DE-627)NLM34957443X | ||
035 | |a (NLM)36444589 | ||
035 | |a (PII)90368 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a El-Ashmawy, Nahla E |e verfasserin |4 aut | |
245 | 1 | 0 | |a Blocking of The Prostaglandin E2 Receptor as a Therapeutic Strategy for Treatment of Breast Cancer |b Promising Findings in a Mouse Model |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.11.2022 | ||
500 | |a Date Revised 17.02.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: The study aimed to investigate the anticancer effect of E-prostanoid receptor 1 (EP1) antagonist, SC19220, alone or in combination with the COX-2 inhibitor Celecoxob(CXB)® in mice bearing solid Ehrlich carcinoma (SEC) | ||
520 | |a METHODS: The tumors were induced in 40 female mice, which were divided randomly into four equal groups (n= 10 in each group): Tumor control, CXB, EP1 antagonist, and co-treatment. CXB (10mg/kg) and EP1 antagonist (2mg/kg) were given intraperitoneally every three days, six times in total, then tissue was extracted and prepared for histopathology and measurement of weight, PGE2, and gene expression of EP1 and β 1 integrin | ||
520 | |a RESULTS: Both inhibitors, alone or in combination, showed a significant (p<0.001) antitumorigenic effect by decreasing, significantly (p<0.001), each of the tumor weights, tumor volumes, PGE2 levels, EP1 and β1-integrin gene expression along with increasing, significantly (p<0.001), the P53 tumor suppressor protein. The survival rate was improved from 80% in the control group to reach 100% in the treated groups. The co-treatment by CXB and EP1 antagonist showed a marked decrease in tumor weights and volumes as compared with the single treatment. In parallel, the histopathological findings showed enhanced apoptosis and diminished necrosis in the co-treated group | ||
520 | |a CONCLUSION: EP1 antagonist proved an antitumorigenic effect alone or combined with CXB and could play a new therapeutic strategy against breast cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Celecoxib | |
650 | 4 | |a Ehrlich Carcinoma | |
650 | 4 | |a PGE2 | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a β 1-integrin | |
650 | 7 | |a Dinoprostone |2 NLM | |
650 | 7 | |a K7Q1JQR04M |2 NLM | |
650 | 7 | |a Receptors, Prostaglandin |2 NLM | |
650 | 7 | |a Integrins |2 NLM | |
700 | 1 | |a El-Zamarany, Enas A |e verfasserin |4 aut | |
700 | 1 | |a Khedr, Eman G |e verfasserin |4 aut | |
700 | 1 | |a Selim, Hend M |e verfasserin |4 aut | |
700 | 1 | |a Khedr, Naglaa F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Asian Pacific journal of cancer prevention : APJCP |d 2000 |g 23(2022), 11 vom: 01. Nov., Seite 3763-3770 |w (DE-627)NLM124868932 |x 2476-762X |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2022 |g number:11 |g day:01 |g month:11 |g pages:3763-3770 |
856 | 4 | 0 | |u http://dx.doi.org/10.31557/APJCP.2022.23.11.3763 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2022 |e 11 |b 01 |c 11 |h 3763-3770 |